section name header

Evidence summaries

Epinephrine for Bronchiolitis

Epinephrine appears to be more effective than placebo for bronchiolitis in outpatients. There is insufficient evidence to support its use in inpatients. Level of evidence: "B"

A Cochrane review [Abstract] 1 included 19 studies with a total of 2 256 children less than two years with acute viral bronchiolitis. Epinephrine versus placebo among outpatients showed a significant reduction in admissions at day 1 (RR 0.67, 95% CI 0.50 to 0.89; 5 studies, n=995) but not at day 7 (RR 0.81, 95% CI 0.63 to 1.03; 3 studies, n=875). There was no difference in length of stay (LOS) for inpatients. Epinephrine versus salbutamol showed no differences among outpatients for admissions at day 1 or 7. Inpatients receiving epinephrine had a significantly shorter LOS compared to salbutamol (MD -0.28, 95% CI -0.46 to -0.09; 4 studies, n=261). One large outpatient study showed a significantly lower admission rate at day 7 for epinephrine and steroid combined versus placebo (RR 0.65, 95% CI 0.44 to 0.95; 1 study, n=400). There were no important differences in adverse events.

Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison).

References

  • Hartling L, Bialy LM, Vandermeer B et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev 2011;(6):CD003123. [PubMed]

Primary/Secondary Keywords